[Federal Register Volume 64, Number 156 (Friday, August 13, 1999)]
[Notices]
[Page 44232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-20938]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: A Basal Cell Carcinoma
Tumor Suppressor Gene
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
U.S. Patent Application Serial No. 08/857,636 filed May 16, 1997
entitled ``A Basal Cell Carcinoma Tumor Suppressor Gene'', PCT
application US97/08433 filed May 16, 1997 designating all countries,
except the U.S., entitled, ``A Basal Cell Carcinoma Tumor Suppressor
Gene'' to Ontogeny, Inc., having a place of business in Cambridge, MA.
The United States of America is the assignee or the exclusive licensee
of the patent rights in this invention.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before October
12, 1999.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to Richard U. Rodriguez, M.B.A., at the Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-
7056, ext. 287; Facsimile: (301) 402-0220; E-mail: rr154z@nih.gov.
SUPPLEMENTARY INFORMATION: In an effort to develop a method of
detection and an efficacious treatment for basal cell carcinoma, nevoid
basal cell carcinoma syndrome, and medulloblastoma, the inventors posit
that the Basal Cell Carcinoma Tumor Suppressor Gene and the disclosed
mutations thereof may play a key physiological role.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be limited to the fields of human
diagnostics and therapeutics for indications consisting of nevoid basal
cell carcinoma syndrome, basal cell carcinoma, and medulloblastoma and
may be granted unless, within 60 days from the date of this published
Notice, NIH receives written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 6, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 99-20938 Filed 8-12-99; 8:45 am]
BILLING CODE 4140-01-M
